BiotechTube

Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy group

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Chronic Kidney Disease Stage 4

Conditions

Chronic Kidney Disease Stage 4

Trial Timeline

Jul 10, 2025 → Dec 30, 2027

NCT ID
NCT07027774

About Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy group

Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy group is a approved stage product being developed by Jiangsu Hengrui Medicine for Chronic Kidney Disease Stage 4. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07027774. Target conditions include Chronic Kidney Disease Stage 4.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Kidney Disease Stage 4 were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07027774ApprovedRecruiting

Competing Products

20 competing products in Chronic Kidney Disease Stage 4

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
25
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
19
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
30